Helius Medical Technologies, Inc.

HSDT

US42328V8019

Advanced Medical Equipment & Technology

Market Closed - Nasdaq Other stock markets 01:30:00 23/05/2024 am IST			5-day change	1st Jan Change
1.43 ^USD	+4.38%		-8.92%	-82.21%

13/05	Transcript : Helius Medical Technologies, Inc., Q1 2024 Earnings Call, May 13, 2024
13/05	Earnings Flash (HSDT) HELIUS MEDICAL TECHNOLOGIES Posts Q1 Revenue $135,000	MT

Helius Medical Technologies, Inc. Provides Unaudited Revenue Guidance for the Fourth Quarter of 2021

January 27, 2022 at 03:23 am IST

Helius Medical Technologies, Inc. provided unaudited revenue guidance for the fourth quarter of 2021. For the quarter, the company expects revenues to be between $250,000 and $260,000.

Latest news about Helius Medical Technologies, Inc.

Transcript : Helius Medical Technologies, Inc., Q1 2024 Earnings Call, May 13, 2024	14/05
Earnings Flash (HSDT) HELIUS MEDICAL TECHNOLOGIES Posts Q1 Revenue $135,000	14/05	MT
Earnings Flash (HSDT) HELIUS MEDICAL TECHNOLOGIES Posts Q1 Revenue $135,000, vs. Street Est of $0.1M	14/05	MT
Exchange-Traded Funds Lower, Equity Futures Mixed Pre-Bell Tuesday as Traders Assess Earnings	07/05	MT
Top Premarket Decliners	07/05	MT
Helius Medical Technologies Prices $6.4 Million Public Offering	07/05	MT
Top Premarket Gainers	03/05	MT
Helius Medical Technologies, Inc. Expands Stroke Clinical Program with Participation of Shepherd Center	24/04	CI
Top Premarket Gainers	03/04	MT
Helius Medical Technologies, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	29/03	CI
Transcript : Helius Medical Technologies, Inc., Q4 2023 Earnings Call, Mar 28, 2024	29/03
Helius Medical Technologies, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	29/03	CI
Earnings Flash (HSDT) HELIUS MEDICAL TECHNOLOGIES Reports Q4 Revenue $134,000	29/03	MT
Helius Medical Technologies, Inc. Initiates Open-Label Study for Registrational Program in Stroke	12/03	CI
Helius Medical Technologies, Inc. Secures HCPCS Codes for Portable Neuromodulation Stimulator (PoNS®) Mouthpiece and Controller	04/03	CI
Traders Await Fresh Cues After Powell's Rate-Cut Commentary, Stifling US Equity Futures Pre-Bell	06/02	MT
Exchange-Traded Funds, Equity Futures Mixed Pre-Bell Tuesday as Earnings Flow Intensifies	06/02	MT
Top Premarket Gainers	06/02	MT
Helius Medical Technologies, Inc. Announces Alignment with FDA on Registrational Program for Treatment of Stroke Patients	06/02	CI
Helius Medical Technologies, Inc. Announces Further Expansion of Stroke Clinical Program with the Addition of Brooks Rehabilitation Hospital	11/01	CI
Earnings Flash (HSDT) HELIUS MEDICAL TECHNOLOGIES Reports Q3 Revenue $143,000	10/11	MT
Earnings Flash (HSDT) HELIUS MEDICAL TECHNOLOGIES Reports Q3 Revenue $143,000	10/11	MT
Helius Medical Technologies, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	10/11	CI
Transcript : Helius Medical Technologies, Inc., Q3 2023 Earnings Call, Nov 09, 2023	10/11
Helius Medical Technologies, Inc. Announces Impairment Charges for the Three Months Ended September 30 2023	10/11	CI

Chart Helius Medical Technologies, Inc.

Duration

Period

More charts

Helius Medical Technologies, Inc. is a neurotech company in the medical device field. It is focused on neurologic deficits using orally applied technology platform that amplifies the brainâs ability to engage physiologic compensatory mechanisms enhancing the lives of people dealing with neurologic diseases. It develops, licenses, or acquires non-implantable technologies targeted at reducing symptoms of neurological disease or trauma. Its product Portable Neuromodulation Stimulator (PoNS) is a non-implantable medical device, inclusive of a controller and mouthpiece, which delivers mild electrical stimulation to the surface of the tongue to provide treatment of gait deficit and chronic balance deficit. PoNS Therapy is integral to the overall PoNS solution and is the physical therapy applied by patients during use of the PoNS neuromodulation stimulator. PoNS is used as an adjunct to a supervised therapeutic exercise program in patients 22 years of age and over by prescription only.

Sector

Advanced Medical Equipment & Technology

Calendar

08/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Helius Medical Technologies, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

1.43 USD

Average target price

4 USD

Spread / Average Target

+179.72%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Advanced Medical Equipment & Technology

	1st Jan change	Capi.
HELIUS MEDICAL TECHNOLOGIES, INC.	-82.21%	53.49L
THERMO FISHER SCIENTIFIC	+11.31%	23TCr
DANAHER CORPORATION	+15.50%	20TCr
INTUITIVE SURGICAL, INC.	+18.83%	14TCr
BOSTON SCIENTIFIC CORPORATION	+30.38%	11TCr
SIEMENS HEALTHINEERS AG	+2.62%	6.53TCr
EDWARDS LIFESCIENCES CORPORATION	+18.31%	5.44TCr
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	+4.96%	5.09TCr
AGILENT TECHNOLOGIES, INC.	+9.95%	4.48TCr
GE HEALTHCARE TECHNOLOGIES INC.	+4.27%	3.68TCr

Other Advanced Medical Equipment & Technology